Advertisement
Rate is lower with tunneled intravenous catheters
Risk reduction guidelines
Too few patients assessed before undergoing biologic dose changes
Don’t stop anti-TNFs, ustekinumab or vedolizumab
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Integrating novel treatment with pioneering research
Study affirms XRT’s utility
A quick review of several advances in risk assessment and treatment
Conditional survival study finds pouch survival improves over time
Immune-mediated factors may be involved
Build the team and listen to its members, this gastroenterology leader advises
Advertisement
Advertisement